OASIS 1 trial: Oral semaglutide 50mg achieves 15.1% weight loss owenhaskins May 23, 2023 2 min read Headline results from OASIS 1 - a phase 3a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities have revealed the trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with oral semaglutide 50mg versus placebo
In many cases, these sleep issues may be linked to other side effects of Mounjaro such as nausea, fatigue, constipation or abdominal discomfort, which can interfere with your ability to get good sleep
However, individual responses to Tirzepatide can vary based on several factors, including dosage, adherence to the prescribed regimen, lifestyle changes, and individual metabolic differences
A person who cannot tolerate higher doses due to GI side effects may still experience transformative health benefits at 5mg, even if the total weight lost is somewhat lower than what higher doses produce
Dr Shauna Levy, an obesity specialist at Tulane University, also said that the libido component is a 'big part of it.' 'We know that GLP-1s affect the reward center of our brain, and for a lot of people, there's reward in sex,' she told DailyMail.com
Chandra et al
